ISU Abxis Co Ltd

086890

Company Profile

  • Business description

    ISU Abxis Co Ltd is engaged in developing and manufacturing therapeutic antibodies in South Korea. It offers Abciximab, Clotinab, Abcertin, and Fabagal used to treat incurable diseases such as cancer and rare diseases.

  • Contact

    3Fl. Kookje Bldg
    90-1 Daeshin-dong
    Seodaemun-gu
    Seoul120-160
    KOR

    T: +82 222278888

    http://www.abxis.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    185

Stocks News & Analysis

stocks

Are small caps finally back?

Does renewed investor interest point to a structural shift in the underperforming factor?
stocks

Chart of the Week: Modest earnings growth at odds with overvalued bank shares

The latest update from our Industry Pulse report.
stocks

Solid start to fiscal 2026 for BHP

Production guidance is maintained by management.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,329.1050.900.55%
CAC 408,225.7818.910.23%
DAX 4024,207.7956.660.23%
Dow JONES (US)46,759.58169.170.36%
FTSE 1009,578.5763.570.67%
HKSE25,967.98186.210.72%
NASDAQ22,965.46225.070.99%
Nikkei 22548,641.61666.18-1.35%
NZX 50 Index13,377.1070.660.53%
S&P 5006,744.1244.720.67%
S&P/ASX 2009,032.8046.600.52%
SSE Composite Index3,922.418.650.22%

Market Movers